Molecular Templates’ Multiple Myeloma Trial Partial Hold Lifted

June 1, 2023

Molecular Templates’ clinical trial for MT-0169, its experimental multiple myeloma therapeutic, is back on, following the US Food and Drug Administration (FDA) lifting a partial hold. The hold was placed on the trial following two adverse events experienced by patients, who both recovered. The move comes after the company laid off half its employees to focus on this drug, along with two others.

According to Lei Lei Wu, “Molecular Templates’ multiple myeloma drug is an engineered toxin body, which features a targeting antibody domain fused to an engineered bacterial protein that induces cell death. The drug targets CD38, which is highly expressed in multiple myeloma cells, in hopes of killing those cells.”

To read more, click here.